- Genenta Science S.p.A. reported a **net loss of €3,826,585** for the six months ended June 30, 2025, an improvement from a net loss of **€4,038,506** for the same period in 2024.  **[1838716_0001493152-25-017756_ex99-1.htm:0]** 
- The company's total operating expenses decreased to **€3,383,093** for the six months ended June 30, 2025, from **€4,518,368** in the prior year period, primarily due to lower research and development and general and administrative expenses.  **[1838716_0001493152-25-017756_ex99-1.htm:0]** **[1838716_0001493152-25-017756_ex99-2.htm:8]** 
- As of June 30, 2025, Genenta had **€17.7 million** in cash, cash equivalents, and marketable securities, which is estimated to fund operations for at least the next twelve months.  **[1838716_0001493152-25-017756_ex99-2.htm:1]** **[1838716_0001493152-25-017756_ex99-1.htm:5]** 
- Financing activities provided **€10.5 million** for the six months ended June 30, 2025, significantly up from **€0.3 million** in the prior year, driven by a **€7.5 million** mandatory convertible bond issuance and **€3.0 million** from its At-the-Market (ATM) program.  **[1838716_0001493152-25-017756_ex99-2.htm:10]** **[1838716_0001493152-25-017756_ex99-1.htm:20]** 
- The company is a clinical-stage biotechnology company with no product revenue, an accumulated deficit of **€59.9 million** as of June 30, 2025, and expects to require additional funding to support its long-term strategy.  **[1838716_0001493152-25-017756_ex99-2.htm:0]** **[1838716_0001493152-25-017756_ex99-2.htm:1]**

Genenta Science S.p.A. (GNTA)